Pfizer Shares Ascend Following Positive Data From Late-Stage Pneumococcal Vaccine Trial For Infants
Pfizer (NYSE: PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD).